Navigation Links
Intrinsic Bioprobes Launches Three New CLIA Approved Mass Spectrometry-Based Tests for Proteins Implicated in Kidney Disease and Renal Failure

TEMPE, Ariz., April 20, 2011 /PRNewswire/ -- Intrinsic Bioprobes Inc. ("IBI") today announced the launch of its first mass spectrometry-based protein assays for in-vitro diagnostic testing. The assays for beta-2-microglobulin, cystatin C, and retinol binding protein are performed on IBI's MASSAY® platform at the CLIA-certified and College of American Pathology (CAP) accredited diagnostic laboratory of the Institute of Genomics Medicine, UMDNJ-New Jersey Medical School.

"The assays are based on IBI's proprietary Mass Spectrometric Immunoassay (MSIA™) technology that in addition to quantification, provides a unique insight into the structural heterogeneity of each protein biomarker," says Dobrin Nedelkov, Ph.D., the CEO and Scientific Director of Intrinsic Bioprobes. The three target proteins - beta-2-microglobulin, cystatin C, and retinol binding protein - are FDA approved clinical markers for in-vitro diagnosis of kidney disease and renal failure. However, all three proteins exhibit structural microheterogeneity that gives rise to protein variants that are not detected by conventional tests. "With these new assays, clinical studies can be initiated to delineate the importance of structural variants in the onset and progression of disease," adds Nedelkov. "We are pleased that we can offer the quality and reproducibility of centralized testing and certify that the assays are performed to the rigorous standards established by CLIA."

"We are excited to perform these assays at our molecular diagnostics laboratory," says Peter Tolias, Ph.D., Professor and Executive Director of the Institute for Genomics Medicine ("IGM"). The Institute is dedicated to biomarker discovery and the clinical evaluation of biomarkers and operates research, development, as well as CLIA-certified CAP-accredited clinical diagnostic testing laboratories. "We have substantial access to patients through our affiliated hospitals and clinics and are interested in undertaking a clinical trial to evaluate structural heterogeneity within these three clinical markers in patients with renal dysfunction," adds Tolias.

Intrinsic Bioprobes Inc. (IBI), located in Tempe, AZ, performs unbiased discovery, verification and population studies on full-length proteins, and discovers and defines microheterogeneity in disease-associated biomarker proteins within healthy and disease populations. IBI's principal focus is the development and application of clinical and diagnostic assays and platforms for rapid and sensitive protein biomarker analysis for early detection and efficient treatment of critical human diseases. IBI's advanced technologies are patented and proprietary process platforms and approaches for proteomic and other research and clinical applications that generally leverage advanced mass spectrometry technology. These approaches include IBI's MASSAY® technology system, its Mass Spectrometric Immunoassay (MSIA™) technology and its Bioreactive Probes (BRP™). The Company has developed a deep and growing base of intellectual property in its field, consisting of 19 issued patents and numerous pending patent applications.

For more information about Intrinsic Bioprobes Inc., please visit


Dobrin Nedelkov
Intrinsic Bioprobes Inc.
Tel. (480) 804-1778

This press release was issued through eReleases(R).  For more information, visit eReleases Press Release Distribution at

SOURCE Intrinsic Bioprobes Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Airo Wireless Announces the Release of the Intrinsically Safe A25is Cell Phone/PDA
2. Intrinsic Bioprobes, Inc. Enters into a $1.27M Contract with the National Cancer Institute to Develop Multiplex Mass Spectrometric Immunoassays for Detection of Low Abundance Cancer-Related Proteins
3. ePharmaSolutions Launches New Application to Streamline Single Sign-On and User Account Provisioning for Sponsors Using Multiple Clinical Trial Technologies
4. Mylan Launches Generic Version of Sandostatin®
5. Rules-Based Medicine Launches OncologyMAP® to Advance Cancer-Related Drug and Diagnostic Development
6. Finesse Launches the VirtualTransmitter Module and TruFluor Transmitter Blades for Seamless Integration of Single-Use Sensors Into Bioreactor Control
7. Intrasphere Technologies Launches SafetyXpress(TM) for Oracle(R) Argus Safety
8. Sigma® Life Science Launches Suite of Knockout Rats to Model Parkinsons Disease
9. M-3 Information, a Leader in Expert Behavioral Health Solutions, Launches
10. Sigma® Life Science Launches Pre-designed CompoZr® Knockout Zinc Finger Nucleases for Entire Human Genome
11. MO BIO Laboratories, Inc. Launches Dye Dots™ Dry Gel Loading Dye
Post Your Comments:
(Date:6/23/2016)... , ... June 23, 2016 , ... ... pleased to announce the launch of their brand, UP4™ Probiotics, into Target stores ... 35 years, is proud to add Target to its list of well-respected retailers. ...
(Date:6/23/2016)... June 23, 2016 Houston Methodist Willowbrook ... Cy-Fair Sports Association to serve as their official ... Houston Methodist Willowbrook will provide sponsorship support, athletic ... with association coaches, volunteers, athletes and families. ... Cy-Fair Sports Association and to bring Houston Methodist ...
(Date:6/23/2016)... SAN FRANCISCO , June 23, 2016   ... it has secured $1 million in debt financing from ... to ramp up automation and to advance its drug ... for its new facility. "SVB has been ... goes beyond the services a traditional bank would provide," ...
(Date:6/23/2016)... , June 23, 2016 Apellis Pharmaceuticals, ... 1 clinical trials of its complement C3 inhibitor, ... and multiple ascending dose studies designed to assess ... of subcutaneous injection in healthy adult volunteers. ... either as a single dose (ranging from 45 ...
Breaking Biology Technology:
(Date:6/9/2016)... in attendance control systems is proud to announce the introduction of fingerprint attendance control ... right employees are actually signing in, and to even control the opening of doors. ... ... ... Photo - ...
(Date:6/2/2016)... 2016 The Department of Transport Management ... 44 million US Dollar project, for the , ... Personalization, Enrolment, and IT Infrastructure , to ... and implementation of Identity Management Solutions. Numerous renowned international vendors ... Decatur was selected for the most compliant and ...
(Date:5/24/2016)... Ampronix facilitates superior patient care by providing unparalleled technology to leaders of the medical ... premium product recently added to the range of products distributed by Ampronix. ... ... ... Ampronix News ...
Breaking Biology News(10 mins):